During the follow-up, the clinical outcomes were better in the PELD group, and the levels of C-reactive protein, creatine phosphokinase, and interleukin 6 were all lower in the PELD group than in the OD group. The gene discussed is CRP; the disease is severe neurodegenerative syndrome with lipodystrophy.